Cell Source, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLCS research report →
Companywww.cell-source.com
Cell Source, Inc. , a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.
- CEO
- Itamar Shimrat
- IPO
- 2014
- Employees
- 1
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $37.83M
- P/E
- -7.37
- P/S
- 0.00
- P/B
- -1.87
- EV/EBITDA
- -13.27
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 27.73%
- ROIC
- 44.09%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,771,046 · 10.34%
- EPS
- $-0.15 · 11.76%
- Op Income
- $-3,848,500
- FCF YoY
- -14.32%
Performance & Tape
- 52W High
- $2.25
- 52W Low
- $0.18
- 50D MA
- $0.83
- 200D MA
- $0.61
- Beta
- -157.98
- Avg Volume
- 3.08K
Get TickerSpark's AI analysis on CLCS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 10, 22 | Verstraete George | other | 0 |
| Aug 9, 21 | Soave Darlene | other | 800,000 |
| Jun 30, 21 | ZOLTY DAVID | other | 4,860 |
| Jun 30, 21 | Soave Darlene | other | 59,507 |
| Jun 30, 21 | Brown Dennis M | other | 2,976 |
| Jun 30, 21 | FRIEDMAN BENZION ABRAHAM | other | 19,440 |
| Dec 29, 20 | ZOLTY DAVID | other | 4,941 |
| Jun 30, 20 | ZOLTY DAVID | other | 4,887 |
| Dec 31, 19 | ZOLTY DAVID | other | 6,420 |
| Jun 26, 19 | ZOLTY DAVID | other | 1,339 |
Our CLCS Coverage
We haven't published any research on CLCS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLCS Report →